Screening people with Alzheimer's disease for possible future studies
Checks whether adults with Alzheimer's disease may qualify for later research studies.
Plain-language title generated from the registry record
Registry title: Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Key facts
- Where
- Buenos Aires, C. A. B. A., Mendoza, Rosario, and San Miguel de Tucumán, ArgentinaSee the 6 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT07177352, who can take part
Where in Argentina
- Hospital Italiano de Buenos AiresBuenos Aires, ArgentinaTaking people
- INECOBuenos Aires, ArgentinaTaking people
- CIERC. A. B. A., ArgentinaNo longer taking part
- Fundacion ScherbovskyMendoza, ArgentinaTaking people
- INECO Neurociencias OroñoRosario, ArgentinaTaking people
- Sanatorio del Sur S.A.San Miguel de Tucumán, ArgentinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07177352
- Record updated
- 19 October 2026
- Original description
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.Read full original descriptionShow less
Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Inclusion: Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges); Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study.
Exclusion: For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary; Dependency in basic activities of daily living (bADLs) due to cognitive impairment; Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted); Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD; History of severe, clinically significant central nervous system trauma; Any serious medical condition that precludes a participant's safe participation and completion of a clinical study.